证券代码：600624 证券简称：复旦复华 公告编号：2024-025 上海复旦复华科技股份有限公司 关于召开 2023 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2024 年 06 月 21 日(星期五)至 06 月 27 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 forward@forwardgroup.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 上海复旦复华科技股份有限公司（以下简称"公司"）已于 2024 年 4 月 30 日发布公司 2023 年年度报告，为便于广大投资者更全面深入地了解公司 2023 年度经营成果、财务状况，公司计划于 2024 年 06 月 28 日下午 15:00- 16:30 举行 2023 年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投 ...

| 1、出席会议的股东和代理人人数 | 16 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 216,081,102 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 31.8072 | | 份总数的比例（%） | | 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 证券代码：600624 证券简称：复旦复华 公告编号：2024-024 上海复旦复华科技股份有限公司 (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 (一) 股东大会召开的时间：2024 年 6 月 5 日 (二) 股东大会召开的地点：上海市奉贤区茂园路 50 号 37 号楼 16 楼第一会议 室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 本次股东大会由公司董事会召集，公司董事长宋正先生主持。本次会议以现 场和网络投票相结合的方式对股东大会通知中列明的 ...

北京观稻中茂（上海）律师事务所 关于 上海复旦复华科技股份有限公司 2023年年度股东大会 7 法律意见书 二〇二四年六月 观韬中茂律师事务所 Guantao Law Firm 地址:上海市长宁区仙霞路 99 号尚嘉中心 12、22 层(200051) Add: 12&22F,L'Avenue No.99 XianXia Rd,Changning District,Shanghai,PRC 电话 Tel: +86 21 23563298 传真 Fax: +86 21 23563299 邮箱 Email: guantaosh@guantao.com 网址 Website: http://www.guantao.com 观 铭中节 (上海)律师事务所 地址:上海市长宁区仙霞路 99号尚嘉中心 12、22层(200051) Add: 12&22F.I.'Avenue No.99 XianXia Rd.Changning District.Shanghai.PRC 电话 Tel: +86 21 23563298 传真 Fax: +86 21 23563299 邮箱 Email: guantaosh@guantao.c ...

上海复旦复华科技股份有限公司（以下简称"公司"）于 2024 年 5 月 30 日收到 了上海国际经济贸易仲裁委员会（上海国际仲裁中心）寄来的《<关于宁波美丽人生 医药生物科技发展有限公司之股权收购协议>争议仲裁案仲裁通知（上国仲（2024） 第 1492 号）》（以下简称"仲裁通知"）及仲裁申请书等相关法律文书，现将相关情 况公告如下： 一、本次仲裁的情况 （一）本次仲裁所涉事项的基本情况 证券代码：600624 证券简称：复旦复华 公告编号：临 2024-023 上海复旦复华科技股份有限公司 涉及仲裁的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 为增强公司盈利能力、综合竞争能力和持续发展能力，扩充医药产业链、形成 业务协同，公司于 2022 年 4 月 28 日召开的第十届董事会第十二次会议审议通过了 《关于收购宁波美丽人生医药生物科技发展有限公司 51%股权的议案》，董事会同意 公司以自筹资金的方式出资人民币 114,192,102.03 元收购标的公司 51%股权，并签 订了《关于宁波美 ...

上海复旦复华科技股份有限公司 2023 年年度股东大会会议资料 证券代码：600624 证券简称：复旦复华 上海复旦复华科技股份有限公司 2023 年年度股东大会会议资料 二〇二四年六月 1 | | | 2023年年度股东大会议程 现场会议召开时间：2024 年 6 月 5 日下午 2 点整 现场会议地点：上海市奉贤区茂园路 50 号 37 号楼 16 楼会议室 出席人员：1、2024 年 5 月 30 日下午交易结束后登记在册的本公司股东及其授权 委托人； 2、公司董事、监事、高管人员及聘任的股东大会见证律师。 会议议程： 一、介绍出席会议的股东人数及其代表的股份总数。 | 年年度股东大会议程 | 2023 | 3 | | --- | --- | --- | | 年年度股东大会会议须知 | 2023 | 5 | | 年年度股东大会议案表决办法 | 2023 | 6 | | 年度董事会报告 | 2023 | 7 | | 年度监事会报告 | 2023 | 15 | | 年年度报告及报告摘要 | 2023 | 20 | | 年度财务决算报告 | 2023 | 21 | | 年度财务预算报告 | 2024 | 22 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所发布的上市公司分行业信息披露指引《上海证券交易所 上市公司自律监管指引第 3 号——行业信息披露》及《关于做好主板上市公司 2024 年第一季度报告披露工作的重要提醒》相关要求，上海复旦复华科技股份 有限公司下属子公司上海复旦复华药业有限公司 2024 年第一季度主要经营数据 披露如下： | 主营业务分行业情况 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 分行业 | 营业收入 | 营业成本 | 毛利率 （%） | 营业收入 比上年增 | 营业成本 比上年增 | 毛利率比 上年增减 | | | | | | 减（%） | 减（%） | （%） | | 药业 | 77,001,457.59 | 32,066,659.11 | 58.36 | -9.31 | -9.12 | -0.08 | | 主营业务分产品情况 | | | | | | | | 分产品 | 营业收入 | 营业成本 | 毛利 ...

Financial Performance - The net profit attributable to shareholders for 2023 is RMB 5,962,951.73, a significant recovery from a loss of RMB 6,200,241.81 in 2022[4] - Total operating revenue for 2023 is RMB 679,678,938.29, representing a decrease of 13.86% compared to RMB 789,005,422.13 in 2022[19] - The net cash flow from operating activities decreased by 75.01% to RMB 7,033,862.40 from RMB 28,146,459.61 in the previous year[19] - The total assets as of the end of 2023 are RMB 1,797,289,168.52, down 3.75% from RMB 1,867,389,132.02 at the end of 2022[19] - The net assets attributable to shareholders increased slightly to RMB 804,800,130.55, a 0.14% increase from RMB 803,688,525.35 in 2022[19] - Basic earnings per share for 2023 is RMB 0.009, recovering from a loss of RMB 0.009 in 2022[20] - The weighted average return on equity for 2023 is 0.74%, a recovery from -0.75% in 2022[20] - The company reported a significant adjustment in financial data due to prior accounting errors, impacting the reported figures for previous years[24] - The company reported a net profit of CNY 6,796,879.87, a substantial recovery from a loss of CNY 1,931,716.33 in the previous year[65] - The total profit increased by 2,096.98% to CNY 23,482,524.96, driven by gains from asset disposals and improved performance from subsidiaries[64] Revenue and Segment Performance - The company's total revenue for the reporting period was 679.68 million yuan, a decrease of 13.86% compared to the same period last year[32] - The pharmaceutical segment generated revenue of 342.04 million yuan, a decrease of 14.22%, accounting for 50.32% of total revenue[32] - The software segment's revenue was 270.73 million yuan, a decrease of 4.56%, contributing 39.83% to total revenue[34] - The park segment's revenue was 40.12 million yuan, a significant decrease of 50.50%, representing 5.90% of total revenue[36] - The company’s total operating revenue for digestive system drugs was CNY 177.57 million, a decrease of 20.09% year-on-year, with a gross margin of 72.90%[125] - Total operating revenue for neurological system drugs was CNY 81.66 million, a decrease of 8.14% year-on-year, with a gross margin of 43.74%[125] - Total operating revenue for anti-tumor drugs was CNY 12.10 million, a significant decrease of 51.00% year-on-year, with a gross margin of 65.64%[125] Cost Management and Expenses - Operating costs amounted to CNY 385,368,876.25, down 16.53% year-on-year[61] - The company's financial expenses decreased by 26.63% to CNY 14,818,205.67, reflecting better cost management[61] - The income tax expense rose by 456.08% to CNY 16,685,645.09, mainly due to increased taxes from asset sales[65] - The total sales expenses for the reporting period were 14,249.69 million RMB, which is a decrease of 12.06% compared to the previous year[136] - The sales expense ratio increased by 0.97% to 41.61%, slightly higher than the industry average[136] Research and Development - The company increased its R&D investment, completing the project initiation for one new product during the reporting period[33] - R&D investment totaled 41,400,546.18 RMB, accounting for 6.09% of operating revenue, with capitalized R&D making up 15.18% of total R&D investment[80] - The company is focusing on the quality and efficacy consistency evaluation of 289 listed products, with key evaluations completed for several products in 2023[127] - The company is actively pursuing consistency evaluations for several products, including Isosorbide Dinitrate Tablets and Bicalutamide Tablets[133] - The company’s R&D investment for the reporting period amounted to 2,912.48 million RMB, representing 6.80% of the pharmaceutical revenue[133] Market and Industry Trends - The pharmaceutical manufacturing industry achieved a revenue of CNY 2,520.57 billion, a year-on-year decrease of 3.7%[39] - The total profit for the pharmaceutical manufacturing sector was CNY 347.30 billion, reflecting a year-on-year decline of 15.1%[39] - The retail sales of Chinese and Western medicines reached CNY 671 billion in 2023, growing by 5.1% year-on-year[40] - The software industry in China generated software business revenue of CNY 12,325.8 billion in 2023, marking a year-on-year increase of 13.4%[44] - The company is facing challenges due to policy changes in the pharmaceutical industry, leading to a decline in operating performance[54] Strategic Initiatives and Future Outlook - Future outlook includes continued efforts in market expansion and potential new product development to drive revenue growth[21] - The company aims to increase the number of high-quality incubators to 20 and daily new tech enterprises to 200 by 2025, contributing to the growth of emerging industries[50] - The company plans to enhance its pharmaceutical segment by increasing R&D investment and expanding its product line, focusing on specialty and traditional Chinese medicine[165] - The company is actively exploring mergers and acquisitions to diversify its client base and business areas, aiming for asset appreciation and cost reduction[168] - The company anticipates total revenue of 750 million yuan for 2024, with expected operating costs of 420 million yuan and expenses of 320 million yuan[167] Governance and Compliance - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective decision-making and protection of shareholder interests[177] - The board of directors held 7 meetings, with independent directors constituting at least one-third of the board, ensuring compliance with legal requirements[178] - The company has implemented a robust internal control system to enhance management levels and risk prevention capabilities, aligning with its operational needs[181] - The company has not found any insider trading incidents among its directors, supervisors, and senior management during the reporting period[183] - The company has a diverse board with a mix of genders and ages, with the youngest director being 30 years old and the oldest being 61 years old[189]

Financial Performance - The company's operating revenue for Q1 2024 was CNY 155,481,059.50, representing a decrease of 8.54% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 11,103,708.12, a significant decline of 7,050.69% year-over-year[5]. - The basic earnings per share (EPS) was -0.0162 CNY, reflecting a decrease of 8,200.00% compared to the previous year[6]. - The company reported a net loss of RMB 11,523,965.67 for Q1 2024 compared to a profit of RMB 134,242.64 in Q1 2023[18]. - The company reported a net loss of CNY 11,140,434.51 in Q1 2024, compared to a net profit of CNY 284,018.59 in Q1 2023, indicating a significant decline in performance[21]. - The company reported a total comprehensive loss of CNY -14,677,497.18 in Q1 2024, compared to a total comprehensive loss of CNY -3,853,463.87 in Q1 2023[22]. - Basic and diluted earnings per share were both CNY -0.0162 in Q1 2024, compared to CNY 0.0002 in Q1 2023, reflecting a significant decline in profitability per share[22]. Cash Flow and Assets - The net cash flow from operating activities was -CNY 44,759,734.75, indicating a negative trend in cash generation from core operations[5]. - The company experienced a net cash outflow from operating activities of CNY -44,759,734.75 in Q1 2024, compared to CNY -12,328,043.58 in Q1 2023, indicating worsening cash flow issues[25]. - Cash and cash equivalents decreased to RMB 234,857,012.06 from RMB 305,482,145.68 as of December 31, 2023, representing a decline of 23.1%[16]. - Cash and cash equivalents at the end of Q1 2024 stood at CNY 233,660,080.86, down from CNY 253,122,223.69 at the end of Q1 2023, representing a decrease of approximately 7.7%[26]. - Total assets at the end of the reporting period were CNY 1,714,141,972.94, down 4.63% from the previous year[6]. - Total current assets decreased to RMB 989,098,406.01 from RMB 1,064,716,305.51, a decline of 7.1%[16]. - Total non-current assets decreased to RMB 725,043,566.93 from RMB 732,572,863.01, a reduction of 1.04%[17]. - Total liabilities decreased to RMB 883,873,302.52 from RMB 951,788,500.73, a decline of 7.1%[18]. - Total equity decreased to RMB 830,268,670.42 from RMB 845,500,667.79, a reduction of 1.8%[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 61,872[12]. - The largest shareholder, Shanghai Fengxian Investment (Group) Co., Ltd., held 18.74% of the shares[12]. Operational Metrics - Total revenue for Q1 2024 was RMB 155,481,059.50, a decrease of 8.93% compared to RMB 170,001,077.38 in Q1 2023[20]. - Total operating costs for Q1 2024 were RMB 168,920,960.50, slightly decreased from RMB 168,935,699.01 in Q1 2023[20]. - Total revenue from operating activities decreased to CNY 169,522,557.27 in Q1 2024, down from CNY 194,114,784.34 in Q1 2023, reflecting a year-over-year decline of approximately 12.6%[25]. - The company's operating profit turned negative at CNY -12,093,127.17 in Q1 2024, compared to a positive operating profit of CNY 3,310,585.41 in the same period last year[21]. - Research and development expenses decreased to CNY 8,191,675.26 in Q1 2024 from CNY 9,253,798.88 in Q1 2023, showing a reduction of about 11.5%[21]. Financial Expenses and Impairments - The company incurred financial expenses of CNY 3,859,616.48 in Q1 2024, an increase from CNY 2,477,266.26 in Q1 2023, marking a rise of approximately 55.7%[21]. - The company’s total assets impairment losses were reported at CNY 398,083.76 in Q1 2024, compared to CNY 1,064,619.84 in Q1 2023, indicating a decrease in asset impairment losses[21]. Strategic Focus - The company is focusing on improving its financial performance and exploring new strategies to enhance market presence[10].

上海复旦复华科技股份有限公司（以下简称"公司"或"复旦复华"）于近期 收到中国证券监督管理委员会上海监管局下发的《关于对上海复旦复华科技股份有 限公司采取责令改正措施的决定》（沪证监决〔2024〕94 号）（以下简称"《决定 书》"），上海证监局决定对公司采取责令改正的行政监管措施，并要求公司对《决 定书》指出的问题进行整改。具体详见公司于 2024 年 3 月 20 日在上海证券交易所 网站（www.sse.com.cn）披露的《上海复旦复华科技股份有限公司关于收到中国证 券监督管理委员会上海监管局＜行政监管措施决定书＞的公告》。 收到《决定书》之后，公司高度重视，向公司全体董事、监事、高级管理人员 （以下简称"董监高"）及相关人员进行了通报、传达，并召集相关部门和人员对 《决定书》中涉及的问题进行了全面梳理和针对性地分析讨论，同时根据相关法律 法规、规范性文件及公司各项管理制度的规定和要求，结合公司实际情况，按照《决 定书》中的要求逐项梳理并认真落实整改措施。 公司于 2024 年 4 月 16 日以通讯方式召开公司第十一届董事会第二次会议，本 次会议的通知和资料已于 2024 年 4 月 12 日送达全 ...

上海复旦复华科技股份有限公司（以下简称"公司"）于 2024 年 4 月 1 日收到 《上海铁路运输法院民事判决书（（2023）沪 7101 民初 500 号）》，现将相关情况公 告如下： 一、本次诉讼的基本情况 1、公司于 2023 年 3 月 15 日收到了《上海铁路运输法院应诉通知书（（2023） 沪 7101 民初 500 号）》及民事起诉状等相关法律文书，上海泉淳实业发展有限公司 因单位借款合同纠纷对公司提起诉讼。详见公司于 2023 年 3 月 17 日披露的《上海 复旦复华科技股份有限公司涉及诉讼的公告》。 2、公司于 2024 年 1 月 16 日收到《上海铁路运输法院民事裁定书（（2023）沪 7101 民初 500 号）》，申请人上海泉淳实业发展有限公司向上海铁路运输法院申请， 请求继续保全被申请人上海复旦复华科技股份有限公司银行存款 31,973,361.11 元 或查封、扣押其相应价值的财产，并已提供保单保函作为担保。上海铁路运输法院 1 案件所处的诉讼阶段：一审判决 上市公司所处的当事人地位：被告 涉案金额：人民币 2,000 万元整及利息 是否会对上市公司损益产生负面影响：鉴于涉诉 ...